Kenvue has completed its worldwide agency review, appointing WPP and Publicis Groupe as its principal global agency partners, according to a recent international report.
As part of the new structure, WPP will assume responsibility for creative strategy and production across Kenvue’s brand portfolio in all markets and channels, with the exception of Neutrogena.
Publicis Groupe will oversee media, commerce, healthcare communications, and technology services for all Kenvue brands globally. In addition, Publicis will manage creative and production duties specifically for Neutrogena. The group already handles Kenvue’s media operations across the Asia-Pacific region, further strengthening its expanded remit.
The review evaluated Kenvue’s entire global brand lineup, which includes major consumer health brands such as Tylenol, Listerine, and Neutrogena. As per COMvergence estimates cited in the report, Kenvue’s global media expenditure reached approximately $1.35 billion in 2025.
The agency consolidation comes at a critical moment for the company, particularly for Tylenol. The brand faced heightened scrutiny in 2025 following concerns raised by the Trump administration regarding the use of acetaminophen during pregnancy—assertions that were widely disputed by the medical community. During this period, Kenvue adopted a cautious, science-backed communication approach as legal matters progressed.
The review also aligns with recent leadership changes within Kenvue. In October 2025, the company appointed Jon Halvorson to a newly created role that combines global marketing oversight with digital commerce leadership, signaling a sharper focus on integrated brand and growth strategies.
Read more: J&J Kenvue Appoints Publicis Media for APAC
